Enabling the next level of pluripotent stem-cell based therapies, from bench to commercializationPublished: July 15, 2019
Stem cell-based therapies require innovative solutions to close the gaps existing between research and commercialization.
Allogeneic cell therapy indications that target large patient populations will necessitate the use of flexible cell production platforms to meet the increasing demand of cell quantities. In addition, process control and monitoring, along with cell quality, are key parameters in clinical cell therapy product manufacturing. Human pluripotent stem cells (hPSCs) hold great promise for regenerative medicine and therefore, are a key intermediate cell therapy product.
Taking advantage of scalable, stirred tank bioreactors to expand hPSCs in suspension, enables the production of cell quantity required for clinical applications, and enhances process comparability, control and automation. Here we show that high fold expansion of hPSCs in suspension can be achieved in a bioreactor without the need to pass the cells during culture time.
Expanded hPSCs pass cell quality assays of self-renewal and pluripotency, including the expression of hPSC-associated markers, differentiation to cells of the three germ layers and retention of a normal karyotype. Expansion of hPSCs in a closed stirred tank bioreactor not only meets commercial cell quantity demand but also enables automation and inline monitoring, which enhance process control and product quality.
- Learn how moving toward 3D culture platform can elevate your research and commercial viability
- Learn how billions of hPSCs can be produced in a time and labour-effective manner
- Learn how 3D expansion platforms could be used in research, through translational and in commercial product phases
- Learn how Lonza can bring you closer to commercialization
Puspa Pandey, R&D Scientist, Cell & Gene Technologies, Lonza
Dr. Puspa Raj Pandey joined Lonza as an R&D Scientist in Cell Therapy Research and Development group in 2017. He earned his PhD from Department of Medical Microbiology, Immunology and Cell Biology (MMICB), Southern Illinois University. Prior to joining Lonza, Puspa did his postdoctoral research in National Cancer Institute/National Institutes of Health (NCI/NIH), Bethesda, MD.
At Lonza his work focuses on the development of novel technologies for cellular reprogramming of somatic cells to generate iPSCs, growth and expansion of iPSCs in stirred-tank bioreactors and directed differentiation of iPSCs in suspension cultures enabling stem cell-based cell therapies.
Fan Yang, Process Development Senior Manager, Cell & Gene Technologies, Lonza
Dr. Fan Yang is a Sr. Manager in Cell Therapy Development Services at Lonza, She has more than 15 years industry experience in process development of cell therapy products and stem cell differentiation. She has strong expertise in cell product development from concept to manufacturing with working knowledge of FDA regulations. She holds a M.D and a Ph.D.